Advertisement
Singapore markets closed

  • Straits Times Index

    3,292.69
    +10.64 (+0.32%)
     

  • Nikkei

    38,405.66
    +470.90 (+1.24%)
     

  • Hang Seng

    17,763.03
    +16.12 (+0.09%)
     

  • FTSE 100

    8,144.13
    -2.90 (-0.04%)
     

  • Bitcoin USD

    60,044.81
    -2,931.59 (-4.66%)
     

  • CMC Crypto 200

    1,284.86
    -54.20 (-4.05%)
     

  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     

  • Dow

    37,815.92
    -570.17 (-1.49%)
     

  • Nasdaq

    15,657.82
    -325.26 (-2.04%)
     

  • Gold

    2,296.50
    -61.20 (-2.60%)
     

  • Crude Oil

    81.50
    -1.13 (-1.37%)
     

  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     

  • FTSE Bursa Malaysia

    1,575.97
    -6.69 (-0.42%)
     

  • Jakarta Composite Index

    7,234.20
    +78.41 (+1.10%)
     

  • PSE Index

    6,700.49
    -69.15 (-1.02%)
     

The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo

Zacks Equity Research
·4-min read

For Immediate Release

Chicago, IL – April 18, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, Linde plc LIN, Caterpillar Inc. CAT, Salesforce, Inc. CRM, and Wells Fargo & Co. WFC.

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for Eli Lilly, Linde and Caterpillar

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Linde plc and Caterpillar Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

ADVERTISEMENT

You can see all of today’s research reports here >>>

Eli Lilly's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+101.8% vs. +15.6%). The Zacks analyst believes that a solid portfolio of drugs for cancer, diabetes and autoimmune diseases and a solid pipeline for drugs in the area of obesity and Alzheimer’s have been helping the company’s growth.

Yet, generic competition for some drugs, rising pricing pressure and challenges in meeting strong demand for incretin products like Trulicity are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Linde’s shares have outperformed the Zacks Chemical – Specialty industry over the last six months (+20.0% vs. -7.9%). The Zacks analyst believes that stable cash flows arising out of long-term contracts with on-site customers and a substantial backlog have ensured that the company’s earning potential keeps climbing.

However, rising competition for new projects in emerging markets remains a concern. The decrease in U.S. industrial production is also expected to reduce the demand for industrial gases, affecting profits.

(You can read the full research report on Linde here >>>)

Shares of Caterpillar have outperformed the Zacks Manufacturing – Construction and Mining industry over the past year (+59.8% vs. +57.2%). Per the Zacks analyst, the company’s cost-saving actions, strong end-market demand and pricing moves have offset the impact of the supply-chain interruptions and cost pressures. Rising global construction activity has also been a major tailwind.

Yet, slowdown of the Chinese real estate sector and higher cost of materials remain concerns.

(You can read the full research report on Caterpillar here >>>)

Other noteworthy reports we are featuring today include Salesforce, Inc., and Wells Fargo & Co.

Why Haven’t You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Wells Fargo & Company (WFC) : Free Stock Analysis Report

Salesforce Inc. (CRM) : Free Stock Analysis Report

Caterpillar Inc. (CAT) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Linde PLC (LIN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research